Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Interim Management Statement

1 May 2014 07:00

RNS Number : 9960F
Sopheon PLC
01 May 2014
 



Embargoed Release: 07:00hrs Thursday1 May 2014

 

 

SOPHEON PLC

("Sopheon" or the "Company")

 

INTERIM MANAGEMENT STATEMENT

 

Sopheon plc, the internationalprovider of software and services that improve the financial return from innovation and product development investments, announces its first interim management statement for the period from1 January 2014 to the date of this announcement.

 

Following on from the strong performance in the final quarter of 2013, our solid maintenance base, some early license wins and high levels of services activity means that revenue visibility for 2014 already stands at £7.3 million (2013: £7.4 million reported, or £7.1 million on a constant exchange rate basis). As in prior years, the early part of the year was relatively quiet for new license orders, but involved extensive business development progress with both new and existing customers, which we expect to lead to additional license closings as the year progresses.

 

The rapid pace of product releases continued, with the release of Accolade® 9.1, the latest version of our flagship software solution which we described in detail in an announcement last week. We have maintained investment across our business, and since the start of the year have added staff in a number of areas, most notably in our US sales team. As always we continue to watch performance expectations closely when making recruitment decisions. In this regard we continue to emphasise to shareholders that the actual timing and value of individual sales events has substantial impact on reported performance for a given period.

 

On the corporate front, we were pleased to negotiate $3.5m in new debt facilities with Silicon Valley Bank. These facilities bear substantially lower interest than those they replace, reflecting the growing maturity of our business. Furthermore, as noted in our recent annual report, we have been in discussions with major holders of our £2m convertible loan stock which currently matures in January next year, and have agreement in principle for a two year extension. We were however disappointed to learn that Euronext intends to wind down the Alternext Amsterdam segment, a market that we joined recently, in late 2012. As we have stated, we will monitor and evaluate the situation in dialogue with Euronext before concluding on implications. In addition, as we have also noted before, incorrect processing by certain market participants in the Netherlands means that the board is considering a repeat of the share consolidation procedure conducted last summer.

 

Accolade® is a registered trademark of Sopheon plc.

 

For further information contact:

Barry Mence, Chairman

Sopheon plc

+ 44 (0) 1483 685 735

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1483 685 735

Charlotte Stranner / Victoria Bates

finnCap

+ 44 (0) 20 7600 1658

Heather Armstrong

Newgate Threadneedle

+ 44 (0) 20 7653 9842

Claire Verhagen

Citigate First Financial

+ 31 (0) 205 754 010

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Performance solutions including software, expertise, and best-practices to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade® solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle. For the first time, businesses can access a single source of the truth across strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on the AIM Market of the London Stock Exchange and on the Alternext Exchange in the Netherlands. For more information, please visit www.sopheon.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEAKLEDLALEFF
Date   Source Headline
30th Jan 201810:27 amRNSIssue of Equity
29th Jan 20187:00 amRNSTrading Update
4th Jan 20182:05 pmRNSSecond Price Monitoring Extn
4th Jan 20182:00 pmRNSPrice Monitoring Extension
4th Jan 20187:00 amRNSTrading Update
22nd Dec 20171:01 pmRNSHolding(s) in Company
22nd Dec 201712:37 pmRNSConversion of Loan Stock
8th Dec 20177:00 amRNSAmendment to the Terms of Convertible Loan Stock
9th Nov 20177:00 amRNSCertis Europe Partners with Sopheon
19th Oct 20177:00 amRNSSopheon Funding Award
11th Oct 201710:44 amRNSDirector/PDMR Shareholding
2nd Oct 20177:00 amRNSIssue of Equity
26th Sep 20177:00 amRNSSopheon "Leader" in Strategic Portfolio Management
5th Sep 20177:00 amRNSSopheon's Accolade Software beyond innovation
24th Aug 20177:00 amRNSHalf Yearly Report
21st Jul 201710:32 amRNSDirector Shareholdings
6th Jul 20177:00 amRNSAccolade Release 11.2
29th Jun 20177:00 amRNSNew Approach to Product Development with Accolade
13th Jun 201712:04 pmRNSDirector Shareholdings
8th Jun 201712:09 pmRNSResult of AGM
8th Jun 20177:00 amRNSAGM Statement
26th May 20174:33 pmRNSIssue of Equity
26th Apr 20173:50 pmRNSIssue of Equity
12th Apr 201712:01 pmRNSIssue of Equity
7th Apr 20171:37 pmRNSDirector Shareholdings
31st Mar 20177:00 amRNSDirector Shareholdings
31st Mar 20177:00 amRNSIssue of Equity
23rd Mar 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSAccolade Release 11.1
16th Feb 20177:00 amRNSGrant of Options / PDMR dealing
30th Jan 20177:00 amRNSTrading Update
21st Nov 201611:50 amRNSIssue of Equity
3rd Nov 20168:00 amRNSAccolade Release 11.0
29th Sep 201612:41 pmRNSIssue of Equity
22nd Sep 20169:09 amRNSIssue of Equity
15th Sep 20163:09 pmRNSIssue of Equity
25th Aug 20167:00 amRNSHalf Yearly Report
28th Jul 20165:01 pmRNSHolding(s) in Company
26th Jul 201610:49 amRNSHolding(s) in Company
12th Jul 201610:48 amRNSHolding(s) in Company
29th Jun 20165:32 pmRNSDirector Dealing
16th Jun 20164:22 pmRNSDirector Dealing
14th Jun 20164:18 pmRNSDirector Dealing
10th Jun 20162:13 pmRNSDirector Dealing
9th Jun 201611:37 amRNSResult of AGM
9th Jun 20167:00 amRNSAGM Statement
31st May 20163:09 pmRNSIssue of Equity
5th May 20161:25 pmRNSHolding(s) in Company
4th May 20167:00 amRNSAccolade Release 10.3
3rd May 20161:27 pmRNSDirector Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.